Incorrect text. The article “Diagnosis and Treatment of Peripheral Arterial Disease” (September 1, 2013, p. 306) required a clarification because of a retraction from one of the cited sources. On October 13, 2015, JAMA published a Notice of Retraction regarding reference #25 (Ahimastos AA, et al. JAMA. 2013) because of “an admission of fabricated results by Anna A. Ahimastos, PhD, who is both the first and corresponding author and was responsible for data collection and integrity for the article.” To avoid misleading readers about the effectiveness of ramipril in treating functional limitations in patients with peripheral arterial disease, the last paragraph of the Medications section (p. 309) was rewritten as follows: “The angiotensin-converting enzyme inhibitor ramipril (Altace) has been evaluated for treating functional limitations in patients with PAD. A randomized controlled trial comparing 10 mg of ramipril with placebo in patients with intermittent claudication reported a 77% increase in pain-free walking time and a 123% increase in maximum walking time in the treatment group at six months.²⁵ However, the trial's publication was subsequently retracted when one of the authors admitted to fabricating data collection at one of the study sites (see Editor's Note).” The online version of the article has been clarified.